Introduction
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global recession. It places the pharma sector in the context of other major industry sectors and analyzes the internal dynamics behind pharmaceutical companies' performance.
Scope
*Cross-sector sales analysis before, during and beyond the global recession
*Assessment of high- and low-growth sectors of the prescription pharmaceuticals market
*Discussion of pharma's possible responses to slowing pharma sales growth rates
*Ranking of the top 15 pharma companies over 2005 to 2014
Highlights
The pharma landscape is being reshaped by expiries. This trend has already begun with expiries wiping -3.7 percentage points off the sector's 200508 sales growth rate, turning pharma into one of the slower-growing industry sectors.
The recession has provided some respite for pharma, giving it a stock market boost as it lived up to its defensive reputation and stood as the only sector to achieve positive sales growth. Nevertheless, this only masked the continual expiry-driven decline of pharma sales growth rates.
Between 2009 and 2014, the expiry burden will reach a tipping point, sending year-on-year pharma sales growth rates negative in 2012 and 2013. If pharma is to avoid a continuation of the 200508 stock market revaluation of its worth, it must take action.
Reasons to Purchase
*Assess pharma's sales and stock market performance in relation to other major industry sectors
*Evaluate the strategic shifts within the prescription pharmaceutical market and identify the high- and low-growth sectors of the industry
*Quantify the historical and forecast impact of generics on pharma's sales growth rate